Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Long-Term Investments (2022 - 2024)

OptimizeRx's Long-Term Investments history spans 3 years, with the latest figure at $434000.0 for Q2 2024.

  • On a quarterly basis, Long-Term Investments changed N/A to $434000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $434000.0, a N/A change, with the full-year FY2023 number at $568000.0, down 98.98% from a year prior.
  • Long-Term Investments hit $434000.0 in Q2 2024 for OptimizeRx, down from $501000.0 in the prior quarter.
  • Over the last five years, Long-Term Investments for OPRX hit a ceiling of $55.9 million in Q4 2022 and a floor of $434000.0 in Q2 2024.
  • Historically, Long-Term Investments has averaged $11.6 million across 3 years, with a median of $568000.0 in 2023.
  • The widest YoY moves for Long-Term Investments: up 98.98% in 2023, down 98.98% in 2023.
  • Tracing OPRX's Long-Term Investments over 3 years: stood at $55.9 million in 2022, then tumbled by 98.98% to $568000.0 in 2023, then decreased by 23.59% to $434000.0 in 2024.
  • Business Quant data shows Long-Term Investments for OPRX at $434000.0 in Q2 2024, $501000.0 in Q1 2024, and $568000.0 in Q4 2023.